GLP-1 receptor agonist or SGLT2 inhibitor prescribing became more common for people with type 1 diabetes in recent years, a nationwide cross-sectional analysis found. From 2010 to 2023, the percentage ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback